Literature DB >> 28398609

Potentially functional variants in lncRNAs are associated with breast cancer risk in a Chinese population.

Yue Jiang1,2,3, Fangzhi Du1,2,3, Fei Chen4, Na Qin1,2,3, Zhu Jiang1,2,3, Jin Zhou1,2,3, Tao Jiang1,2,3, Zhening Pu1,2,3, Yue Cheng1,2,3, Jiaping Chen1,2,3, Juncheng Dai1,2,3, Hongxia Ma1,2,3, Guangfu Jin1,2,3, Zhibin Hu1,2,3, Hao Yu2, Hongbing Shen1,2,3.   

Abstract

Long non-coding RNAs (lncRNAs) participate in the development of breast cancer. Genetic variants in lncRNAs may be involved in their abnormal expressions and associated with cancer risk. In the present study, we performed RNA sequencing on five paired breast cancer tumor and adjacent non-cancerous tissues to obtain differentially expressed lncRNAs. We systematically selected potential regulatory variants of these lncRNAs and investigated the associations between these variants and breast cancer susceptibility in 1486 breast cancer cases and 1519 cancer-free controls in a Chinese population. Eleven lncRNAs were significantly differentially expressed between breast cancer tumor and normal tissues (false discovery rate (FDR) ≤0.05 and fold-change ≥2), including two known lncRNAs HOTAIR and UCA1. We subsequently genotyped 20 variants located on these lncRNAs and identified two variants (rs11471161 in AC104135.3 and rs3751232 in RP11-1060J15.4) associated with breast cancer risk. Logistic regression analysis indicated that the variant allele of rs11471161 was significantly associated with a decreased breast cancer risk (additive model: OR = 0.84, 95%CI = 0.74-0.94, P = 0.004), while the variant allele of rs3751232 showed an increased risk of breast cancer (additive model: OR = 1.20, 95%CI = 1.02-1.40, P = 0.027). Further co-expression analysis indicated that AC104135.3 associated with ERBB2, which promotes the development and progression of breast cancer through overexpression. Together, these results suggest that genetic variants rs11471161 and rs3751232 in AC104135.3, and RP11-1060J15.4, respectively, may influence the susceptibility to breast cancer in the Chinese population. Further functional evaluations and larger studies are warranted to validate these findings.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  breast cancer; genetic variants; lncRNAs; susceptibility

Mesh:

Substances:

Year:  2017        PMID: 28398609     DOI: 10.1002/mc.22659

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  5 in total

1.  Detection of lncRNA by LNA-Based In Situ Hybridization in Paraffin-Embedded Cancer Cell Spheroids.

Authors:  Boye Schnack Nielsen; Jesper Larsen; Jakob Høffding; Son Ly Nhat; Natasha Helleberg Madsen; Trine Møller; Bjørn Holst; Kim Holmstrøm
Journal:  Methods Mol Biol       Date:  2021

Review 2.  Long Non-Coding RNA in the Pathogenesis of Cancers.

Authors:  Yujing Chi; Di Wang; Junpei Wang; Weidong Yu; Jichun Yang
Journal:  Cells       Date:  2019-09-01       Impact factor: 6.600

3.  An immune-related lncRNA signature predicts prognosis and adjuvant chemotherapeutic response in patients with small-cell lung cancer.

Authors:  Zhihui Zhang; Yuejun Luo; Chaoqi Zhang; Peng Wu; Guochao Zhang; Qingpeg Zeng; Lide Wang; Liyan Xue; Zhaoyang Yang; Hua Zeng; Bo Zheng; Fengwei Tan; Qi Xue; Shugeng Gao; Nan Sun; Jie He
Journal:  Cancer Cell Int       Date:  2021-12-20       Impact factor: 5.722

4.  lncRNA NUTM2A-AS1 Targets the SRSF1/Trim37 Signaling Pathway to Promote the Proliferation and Invasion of Breast Cancer.

Authors:  Xiaojie Ning; Jianguo Zhao; Fan He; Yuan Yuan; Bin Li; Jian Ruan
Journal:  Comput Math Methods Med       Date:  2022-08-02       Impact factor: 2.809

5.  Downregulation of LINC01140 is associated with adverse features of breast cancer.

Authors:  Deheng Li; Liangdong Li; Yiqun Cao; Xin Chen
Journal:  Oncol Lett       Date:  2019-11-25       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.